Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer.
Najjar YG, Finke JH. Najjar YG, et al. Front Oncol. 2013 Mar 15;3:49. doi: 10.3389/fonc.2013.00049. eCollection 2013. Front Oncol. 2013. PMID: 23508517 Free PMC article.
Novel agents in renal carcinoma: a reality check.
Najjar YG, Rini BI. Najjar YG, et al. Ther Adv Med Oncol. 2012 Jul;4(4):183-94. doi: 10.1177/1758834012443725. Ther Adv Med Oncol. 2012. PMID: 22754592 Free PMC article.
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J. Najjar YG, et al. Clin Cancer Res. 2017 May 1;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. Epub 2016 Oct 31. Clin Cancer Res. 2017. PMID: 27799249 Free PMC article.
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI. Najjar YG, et al. Eur J Cancer. 2014 Apr;50(6):1084-9. doi: 10.1016/j.ejca.2014.01.025. Epub 2014 Feb 19. Eur J Cancer. 2014. PMID: 24559686
An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG, Puligandla M, Lee SJ, Kirkwood JM. Najjar YG, et al. Cancer. 2019 Sep 1;125(17):3013-3024. doi: 10.1002/cncr.32162. Epub 2019 May 8. Cancer. 2019. PMID: 31067358 Free PMC article.
Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma.
Najjar YG, Mittal K, Faza NN, Dushkin H, Peereboom DM. Najjar YG, et al. BMJ Case Rep. 2014 May 5;2014:bcr2013201442. doi: 10.1136/bcr-2013-201442. BMJ Case Rep. 2014. PMID: 24798352 Free PMC article.
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.
Roy S, Pradhan D, Ernst WL, Mercurio S, Najjar Y, Parikh R, Parwani AV, Pai RK, Dhir R, Nikiforova MN. Roy S, et al. Among authors: najjar y. Mod Pathol. 2017 Aug;30(8):1133-1143. doi: 10.1038/modpathol.2017.33. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548125
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.
Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Najjar YG, et al. J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9. J Transl Med. 2017. PMID: 28222797 Free PMC article. Clinical Trial.
Neoadjuvant treatment for melanoma: current challenges and future perspectives.
Najjar YG, Kirkwood JM. Najjar YG, et al. Melanoma Manag. 2016 Jun;3(2):149-159. doi: 10.2217/mmt-2015-0001. Epub 2016 May 25. Melanoma Manag. 2016. PMID: 30190883 Free PMC article. Review.
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.
Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, Zhai S, Kirkwood JM, Delgoffe GM. Najjar YG, et al. JCI Insight. 2019 Mar 7;4(5):e124989. doi: 10.1172/jci.insight.124989. eCollection 2019 Mar 7. JCI Insight. 2019. PMID: 30721155 Free PMC article.
15 results
Jump to page
Feedback